Berenson JR - Search Results

1

Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy.

Bujarski S, Udd K, Soof C, Chen H, Spektor TM, Safaie T, Li M, Stern J, Wang C, Xu N, Emamy-Sadr M, Swift R, Rahbari A, Patil S, Souther E, Regidor B, Sutanto C, Berenson JR. Bujarski S, et al. Among authors: berenson jr. Target Oncol. 2021 Jul;16(4):503-515. doi: 10.1007/s11523-021-00821-6. Epub 2021 Jun 7. Target Oncol. 2021. PMID: 34097243

2

A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma.

Berenson JR, Swift RA, Ferretti D, Purner MB. Berenson JR, et al. Clin Lymphoma. 2004 Sep;5(2):130-4. doi: 10.3816/clm.2004.n.020. Clin Lymphoma. 2004. PMID: 15453931 Clinical Trial. No abstract available.

3

Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma.

Borad MJ, Swift R, Berenson JR. Borad MJ, et al. Among authors: berenson jr. Leukemia. 2005 Jan;19(1):154-6. doi: 10.1038/sj.leu.2403541. Leukemia. 2005. PMID: 15496977 No abstract available.

4

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K. Berenson JR, et al. Cancer. 2005 Nov 15;104(10):2141-8. doi: 10.1002/cncr.21427. Cancer. 2005. PMID: 16206291 Free article. Clinical Trial.

5

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R. Berenson JR, et al. J Clin Oncol. 2006 Feb 20;24(6):937-44. doi: 10.1200/JCO.2005.03.2383. Epub 2006 Jan 17. J Clin Oncol. 2006. PMID: 16418495 Clinical Trial.

6

Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status.

Yeh HS, Chen H, Manyak SJ, Swift RA, Campbell RA, Wang C, Li M, Lee HJ, Waterman G, Gordon MS, Ma J, Bonavida B, Berenson JR. Yeh HS, et al. Among authors: berenson jr. Br J Haematol. 2006 Jun;133(5):526-9. doi: 10.1111/j.1365-2141.2006.06052.x. Br J Haematol. 2006. PMID: 16681640 Free article.

7

LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma.

Campbell RA, Manyak SJ, Yang HH, Sjak-Shie NN, Chen H, Gui D, Popoviciu L, Wang C, Gordon M, Pang S, Bonavida B, Said J, Berenson JR. Campbell RA, et al. Among authors: berenson jr. Int J Oncol. 2006 Jun;28(6):1409-17. Int J Oncol. 2006. PMID: 16685443

8

Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis.

Chen H, Li M, Campbell RA, Burkhardt K, Zhu D, Li SG, Lee HJ, Wang C, Zeng Z, Gordon MS, Bonavida B, Berenson JR. Chen H, et al. Among authors: berenson jr. Oncogene. 2006 Oct 19;25(49):6520-7. doi: 10.1038/sj.onc.1209653. Epub 2006 May 15. Oncogene. 2006. PMID: 16702955

9

Bone complications in multiple myeloma.

Berenson JR, Rajdev L, Broder M. Berenson JR, et al. Cancer Biol Ther. 2006 Sep;5(9):1082-5. doi: 10.4161/cbt.5.9.3307. Epub 2006 Sep 20. Cancer Biol Ther. 2006. PMID: 16969119 Review.

10

Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.

Berenson JR, Boccia R, Siegel D, Bozdech M, Bessudo A, Stadtmauer E, Talisman Pomeroy J, Steis R, Flam M, Lutzky J, Jilani S, Volk J, Wong SF, Moss R, Patel R, Ferretti D, Russell K, Louie R, Yeh HS, Swift RA. Berenson JR, et al. Br J Haematol. 2006 Oct;135(2):174-83. doi: 10.1111/j.1365-2141.2006.06280.x. Br J Haematol. 2006. PMID: 17010047 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

286 results

Search Page